Cargando…
Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis
Macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase-2 (MMP-2) and its specific tissue inhibitor (TIMP-2) may play an important role in the pathogenesis of cancer disease. We investigated the plasma levels and diagnostic power (ROC curve analysis) of M-CSF, MMP-2, TIMP-2 and tumor...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242253/ https://www.ncbi.nlm.nih.gov/pubmed/30820752 http://dx.doi.org/10.1007/s12253-019-00626-z |
_version_ | 1783537205527969792 |
---|---|
author | Lubowicka, Emilia Zbucka-Kretowska, Monika Sidorkiewicz, Iwona Zajkowska, Monika Gacuta, Ewa Puchnarewicz, Andrzej Chrostek, Lech Szmitkowski, Maciej Ławicki, Sławomir |
author_facet | Lubowicka, Emilia Zbucka-Kretowska, Monika Sidorkiewicz, Iwona Zajkowska, Monika Gacuta, Ewa Puchnarewicz, Andrzej Chrostek, Lech Szmitkowski, Maciej Ławicki, Sławomir |
author_sort | Lubowicka, Emilia |
collection | PubMed |
description | Macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase-2 (MMP-2) and its specific tissue inhibitor (TIMP-2) may play an important role in the pathogenesis of cancer disease. We investigated the plasma levels and diagnostic power (ROC curve analysis) of M-CSF, MMP-2, TIMP-2 and tumor markers CA 125 and SCC-Ag in cervical cancer (CC) patients as compared to control group. The study included 89 patients with cervical cancer. The control group consisted of 50 healthy, untreated women. The plasma levels of M-CSF, MMP-2 and TIMP-2 were determined using ELISA, CA 125 and SCC-Ag – by CMIA method. The median levels of M-CSF, TIMP-2, SCC-Ag and CA 125 in the entire group of CC were significantly different than compared to the healthy women group. MMP-2 showed the highest value of sensitivity from all examined parameters (in stage I of CC – 93.10%, II – 82.76%, III and IV – 96.88%, total group – 92.05%). The highest specificity was obtained by M-CSF (86%). The area under the ROC curve (AUC) of M-CSF (0.8051) was the largest of all the tested parameters (even higher than commonly used tumor markers) in the group of cervical cancer. The combination of M-CSF, MMP-2 or TIMP-2 with SCC antigen resulted in an increase AUCs in all cases (0.8760;0.7880;0.8081;respectively). The findings of this study suggest the usefulness of all examined parameters in the diagnostics of CC patients. Out of the tested substances, M-CSF also appears to be the best candidate for cancer diagnostics in all stages of the disease, based on ROC analysis. |
format | Online Article Text |
id | pubmed-7242253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-72422532020-06-03 Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis Lubowicka, Emilia Zbucka-Kretowska, Monika Sidorkiewicz, Iwona Zajkowska, Monika Gacuta, Ewa Puchnarewicz, Andrzej Chrostek, Lech Szmitkowski, Maciej Ławicki, Sławomir Pathol Oncol Res Original Article Macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase-2 (MMP-2) and its specific tissue inhibitor (TIMP-2) may play an important role in the pathogenesis of cancer disease. We investigated the plasma levels and diagnostic power (ROC curve analysis) of M-CSF, MMP-2, TIMP-2 and tumor markers CA 125 and SCC-Ag in cervical cancer (CC) patients as compared to control group. The study included 89 patients with cervical cancer. The control group consisted of 50 healthy, untreated women. The plasma levels of M-CSF, MMP-2 and TIMP-2 were determined using ELISA, CA 125 and SCC-Ag – by CMIA method. The median levels of M-CSF, TIMP-2, SCC-Ag and CA 125 in the entire group of CC were significantly different than compared to the healthy women group. MMP-2 showed the highest value of sensitivity from all examined parameters (in stage I of CC – 93.10%, II – 82.76%, III and IV – 96.88%, total group – 92.05%). The highest specificity was obtained by M-CSF (86%). The area under the ROC curve (AUC) of M-CSF (0.8051) was the largest of all the tested parameters (even higher than commonly used tumor markers) in the group of cervical cancer. The combination of M-CSF, MMP-2 or TIMP-2 with SCC antigen resulted in an increase AUCs in all cases (0.8760;0.7880;0.8081;respectively). The findings of this study suggest the usefulness of all examined parameters in the diagnostics of CC patients. Out of the tested substances, M-CSF also appears to be the best candidate for cancer diagnostics in all stages of the disease, based on ROC analysis. Springer Netherlands 2019-02-28 2020 /pmc/articles/PMC7242253/ /pubmed/30820752 http://dx.doi.org/10.1007/s12253-019-00626-z Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Lubowicka, Emilia Zbucka-Kretowska, Monika Sidorkiewicz, Iwona Zajkowska, Monika Gacuta, Ewa Puchnarewicz, Andrzej Chrostek, Lech Szmitkowski, Maciej Ławicki, Sławomir Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis |
title | Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis |
title_full | Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis |
title_fullStr | Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis |
title_full_unstemmed | Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis |
title_short | Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis |
title_sort | diagnostic power of cytokine m-csf, metalloproteinase 2 (mmp-2) and tissue inhibitor-2 (timp-2) in cervical cancer patients based on roc analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242253/ https://www.ncbi.nlm.nih.gov/pubmed/30820752 http://dx.doi.org/10.1007/s12253-019-00626-z |
work_keys_str_mv | AT lubowickaemilia diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis AT zbuckakretowskamonika diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis AT sidorkiewicziwona diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis AT zajkowskamonika diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis AT gacutaewa diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis AT puchnarewiczandrzej diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis AT chrosteklech diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis AT szmitkowskimaciej diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis AT ławickisławomir diagnosticpowerofcytokinemcsfmetalloproteinase2mmp2andtissueinhibitor2timp2incervicalcancerpatientsbasedonrocanalysis |